Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Williams

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
American Journal of Ophthalmology|December 16, 2018
The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of RanibizumabPhilip P Storey, Zujaja Tauqeer, Yoshihiro Yonekawa, et al.
Cell Reports. Medicine|January 27, 2024
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancerMatthew D Galsky, Xiangnan Guan, Deepali Rishipathak, et al.
Cancer Cell|November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockadeHabib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Nature Human Behaviour|September 24, 2025
Measuring the semantic priming effect across many languagesErin M Buchanan, Kelly Cuccolo, Tom Heyman, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
American Journal of Ophthalmology|December 16, 2018
The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of RanibizumabPhilip P Storey, Zujaja Tauqeer, Yoshihiro Yonekawa, et al.
Cell Reports. Medicine|January 27, 2024
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancerMatthew D Galsky, Xiangnan Guan, Deepali Rishipathak, et al.
Cancer Cell|November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockadeHabib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Nature Human Behaviour|September 24, 2025
Measuring the semantic priming effect across many languagesErin M Buchanan, Kelly Cuccolo, Tom Heyman, et al.
Pageof 6